Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B A Pulaski

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 1998
IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytesK Y Yeh, A J McAdam, B A Pulaski, et al.
International Journal of Cancer|May 29, 1995
Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cellsA J McAdam, B A Pulaski, S S Harkins, et al.
Cellular Immunology|October 15, 1995
Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumorA J McAdam, B A Pulaski, E Storozynsky, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 16, 1996
Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cellsB A Pulaski, K Y Yeh, N Shastri, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1994
Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytesA J McAdam, A Felcher, M L Woods, et al.
Cellular Immunology|October 15, 1995
B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinomaK Y Yeh, B A Pulaski, M L Woods, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 1998
IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytesK Y Yeh, A J McAdam, B A Pulaski, et al.
International Journal of Cancer|May 29, 1995
Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cellsA J McAdam, B A Pulaski, S S Harkins, et al.
Cellular Immunology|October 15, 1995
Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumorA J McAdam, B A Pulaski, E Storozynsky, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 16, 1996
Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cellsB A Pulaski, K Y Yeh, N Shastri, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1994
Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytesA J McAdam, A Felcher, M L Woods, et al.
Cellular Immunology|October 15, 1995
B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinomaK Y Yeh, B A Pulaski, M L Woods, et al.
Pageof 2